Yuling Luo rang the Nasdaq closing bell Friday having taken his first firm public in a massively oversubscribed spherical. The Alamar Biosciences CEO’s IPO was one in all two back-to-back blockbuster biotech choices this week, a transparent sign that traders are prepared to open their wallets for all times sciences firms once more—below the suitable situations.
On Thursday, Kailera Therapeutics, an weight problems drug developer, raised $625 million in what’s believed to be the most important biotech IPO in Nasdaq historical past. The IPO priced 39.1 million shares at $16 (the highest of its vary). The corporate had initially got down to increase simply $500 million. At some point post-IPO, Kailera was already up 63 %.
On Friday, Alamar Biosciences, a precision proteomics (the examine of proteins quite than genes) agency, priced its personal upsized providing at $17 per share (the highest of its vary) elevating $191.3 million after demand exceeded out there shares by 11 occasions, Luo informed Fortune. Very similar to Kailera, Alamar shares soared, up 33% on the primary day of buying and selling.
For Alamar particularly, the itemizing carries symbolic weight. The life sciences instruments and diagnostics sector has been successfully shut out of the general public markets since 2021, when
MedTech IPO exercise peaked at 61 firms going public. A brutal stretch adopted: Solely two U.S. MedTech firms went public in every of 2022 and 2023, in keeping with FLG Companions information. The instruments sub-sector, the place Alamar operates, has remained dormant.
Luo attributed the IPO drought—and Alamar’s capability to finish it—to a long-awaited technological breakthrough in early illness detection of most cancers and Alzheimer’s. The corporate’s platform can detect illness alerts in blood which are too faint for current instruments to choose up. He in contrast the product’s detection capabilities as having the ability to learn a watch examination chart from 37 miles away.
“I think that’s why it’s been five years, because investors now see the great potential in proteomics. Everyone recognizes we finally have technology that could unlock it,” Luo informed Fortune. He sees proteomics as the following frontier after genomics: the place gene-sequencing offers medical doctors a static snapshot of a affected person’s DNA, protein evaluation affords a real-time window into how illness is definitely unfolding contained in the physique.
Alamar operates in a market valued at over $36 billion in 2025 and anticipated to achieve $65.8 billion by 2030. The corporate tripled income from $25 million to $74 million in two years regardless of what Luo referred to as “one of the most difficult market environments” for the instruments business.
Kailera is staking its declare in a good hotter alternative and area: the worldwide weight problems GLP-1 market, presently value roughly $10 billion and projected to achieve $66.57 billion by 2035, rising at a 23% CAGR. The corporate goes head-to-head with Novo Nordisk and Eli Lilly, creating injectable and oral GLP-1 agonists.
The back-to-back pricings arrive at a sophisticated second for biotech extra broadly. Non-public bio/pharma funding in 2025 totaled roughly $40 billion throughout 1,045 offers, basically flat with 2024. In the meantime, the general enterprise market has been dominated by AI. About 80% of worldwide enterprise capital in Q1 2026 flowed to AI firms, with 4 mega-deals (OpenAI, Anthropic, xAI, and Waymo) accounting for greater than $188 billion of the report $300 billion quarter. That dynamic has squeezed consideration and capital for non-AI sectors, at the same time as PitchBook information confirmed biotech deal exercise climbing again to its highest stage since late 2022 in This fall 2025.
The broader IPO market has struggled to search out its footing too: early 2026 listings have been “much slower than was expected,” Crunchbase analysis lead Gené Teare beforehand informed Fortune, with consideration consumed by AI giants like OpenAI, SpaceX, and Anthropic which have but to checklist. After they do, Teare stated, it may “create a lot of energy in the markets for other companies to also go out”—or just crowd everybody else out.
Analysts had projected 30 to 35 biotech IPOs for 2026. This week’s offers counsel the window could lastly be cracking open—a minimum of for firms with late-stage information and differentiated science to indicate traders.
